Edward Stadtmauer, MD, Section Chief, Hematological Malignancies at the Abramson Center, examines the current state of therapy for the hematological malignancies as reported at ASCO 2016 and ASH 2015. Discussion includes daratumumab/bortezomib/dexamethasone and lenalidomide therapies for multiple myeloma with a review of the continued application of ASCT as adjunctive therapy; rituximab for lymphoma; imatinib in CML with a consideration of discontinuation in long-term users with deep and sustained molecular response and the use of CPX-351 in older patients with newly diagnosed high-risk AML.
Related Links
Published
February 7, 2017
Created by
BROADCASTMED